Over £10m to advance pioneering VR neuro-rehab glasses

Digital software company Strolll has raised £10.35m to advance its augmented reality (AR) glasses for neuro-rehab to patients living with neurological disorders.

Strolll’s platform combines digital content with the real world through the use of off-the-shelf AR glasses that are aimed at helping people living with neurological disorders such as Parkinson’s disease, stroke, and multiple sclerosis.

Patients are able to undergo therapy both within in-clinic and at-home settings, and so far, clinical trials have shown that clinicians using the rehab tech can enable seven times more treatments with 67 per cent less staff time.

The technology helps to improve mobility in patients who struggle to walk, balance or are at risk of falling.

Jorgen Ellis, CEO of Strolll said: “Strolll are at an exciting inflection point in our journey and we are delighted to be partnering with IW Capital, as well as other investment partners, as we look to accelerate the growth of our business.

“We are positioned at the forefront of the neurorehabilitation market and we’re passionate about helping to improve the care that patients with neurological disorders receive. We thank investors for believing in our vision of healthcare and we look forward to building on our achievements to date.”

The technology provides gamification of physiotherapy exercises and enables clinicians to deliver personalised and high dosage immersive neurorehabilitation that improves treatment outcomes.

Strolll has confirmed it will use the investment to accelerate its sales and marketing activities, extend its product leadership and to expand the regulatory label, which will allow the company to target additional neuro-related disorders adjacent to the ones it already addresses.

In July 2024, Strolll began a three-year, £2.4m NIHR grant-funded project with the University of Leeds, University of York and four NHS trusts across the UK to conduct a randomised controlled trial of Strolll as a therapeutic treatment for patients with Parkinson’s disease in real-world healthcare settings.

In the same year, Strolll also entered the US market in a US$3m collaboration with US healthcare provider, Cleveland Clinic. This deal saw Cleveland Clinic transfer IP to Strolll in an exclusive software licensing agreement and become a shareholder in Strolll.

Commenting on the investment, IW Capital’s investment director, Isobel Egemole, said: “IW Capital are thrilled to announce our investment into Strolll.

“Strolll are transforming the physiotherapy and neurorehabilitation markets and have already helped a significant number of people with debilitating neurological disorders to live better lives. The potential impact of their software is huge and we’re proud to be backing this cutting-edge business as it addresses key healthcare needs.”